Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN (Epoetin alfa), NEUPOGEN (Filgrastim), and INFERGEN (Interferon alfacon-1).
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 1998 | 9 Months Ended Sep 30, 1998 |
|---|---|---|
| Total Revenues | $700.9 | $1,963.2 |
| Net Income | $221.0 | $624.6 |
| Diluted EPS | $0.83 | $2.37 |
| Operating Cash Flow (9mo) | $761.5 | |
| Cash & Equivalents (Sep 30, 1998) | $104.1 | |
| Marketable Securities (Sep 30, 1998) | $1,020.8 | |
| Total Debt (Sep 30, 1998) | $328.6 (Long-term: $223.0; Current: $6.0; Commercial Paper: $99.6) | |
| Effective Tax Rate (9mo) | 30.5% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 17.2% year-over-year for the three months ended September 30, 1998 ($700.9M vs. $598.3M). Product sales grew 16.1% to $641.8M.
- Profitability Surge: Net income for the quarter more than doubled to $221.0M from $83.8M in the prior year. This improvement is largely attributable to the absence of a $157M legal assessment charge recorded in Q3 1997 related to Johnson & Johnson arbitration.
- Product Performance:
- EPOGEN: Sales increased 23% ($349.7M) driven by growth in the U.S. dialysis population and higher dosing following HCFA reimbursement policy revisions.
- NEUPOGEN: Sales increased 7% ($287.3M) due to U.S. market demand and price increases, though international sales were slightly impacted by unfavorable currency effects.
- Stock Repurchases: The Company repurchased 11.6 million shares for $692.8M during the nine-month period, substantially completing a $1 billion authorization. A new $1 billion authorization was approved in October 1998.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 1998 Sales Growth: Expected to be in the "very low double digits" for total product sales. EPOGEN growth is projected in the mid-teens; NEUPOGEN in the low-to-mid single digits.
- 1999 Outlook: Total product sales growth expected in the high single to very low double digits. EPOGEN growth expected to remain double-digit but lower than 1998.
- Earnings Per Share:
- 1998: Expected to be slightly above the analyst consensus range of $3.08–$3.18, aided by the reinstatement of the R&E tax credit.
- 1999: Expected to align with analyst estimates of $3.40–$3.55.
- Capital Expenditures: Anticipated to be $350M–$400M in 1998 and $300M–$400M in 1999.
Risks and Contingencies
- Johnson & Johnson Arbitration: Ongoing disputes regarding "spillover" sales of EPOGEN and rights to NESP. While Amgen was successful in the primary arbitration, J&J has filed petitions to vacate cost awards and challenged audit results for 1995–1997. Amgen does not expect a material adverse effect but notes uncertainties.
- Year 2000 Compliance: Amgen is not yet compliant. The assessment is incomplete, and the company is behind schedule on some projects. Estimated total costs range from $40M to $60M. Failure to achieve compliance could materially affect operations.
- Reimbursement Risks: EPOGEN sales are sensitive to federal reimbursement rates (Medicare). NEUPOGEN faces potential coverage limitations under Medicare Part B in certain states and competition in the EU.
- Legal Proceedings: Includes securities class action litigation regarding alleged misrepresentations (1997–1998) and patent infringement suits regarding INFERGEN.
Investor Verification Checklist
- Arbitration Resolution: Monitor the status of the Johnson & Johnson arbitration regarding cost awards and the 1995–1997 audit challenge.
- Year 2000 Progress: Verify the timeline for remediation and testing of critical computer systems, given the current schedule slippage.
- Reimbursement Policy: Track any further changes in HCFA/Medicare reimbursement policies for EPOGEN and NEUPOGEN.
- Stock Repurchase Execution: Confirm the utilization of the newly authorized $1 billion repurchase program.
- INFERGEN Litigation: Follow developments in the patent infringement suit filed by Schering Corporation.